ABVC BioPharma, Inc. (ABVC) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is neutral — 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-4.40 and revenue of $0.02B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.43 vs est $-4.40 (beat +90.2%). 2025: actual $-0.39 vs est $-4.60 (beat +91.5%). Analyst accuracy: 0%.
ABVC Analyst Ratings
Hold
Based on 1 analysts giving stock ratings to ABVC BioPharma, Inc. in the past 3 months
EPS Estimates — ABVC
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.43
vs Est –$4.40
▲ 923.3% off
2025
Actual –$0.39
vs Est –$4.60
▲ 1,079.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ABVC
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.015B
▼ 2,748.2% off
2025
Actual $0.001B
vs Est $0.004B
▼ 424.3% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast significant revenue growth ahead.
